Drugs / Vertebral bone marrow (vBMA) clot
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05947175 | May 2023 → Dec 2026 expected | vertebral column disorder | Rizzoli Orthopaedic Institute | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vertebral bone marrow (vBMA) clot | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947175 ↗ |
| Known as | vertebral BMA clot | “The vertebral BMA clot showed two successful hits since it works as a biological scaffold and as a powerful source of mesenchymal stem cells” PMID 35118056 ↗ Jan 2022 |
| Modality | Cell therapy | “Vertebral body bone marrow aspirate (V-BMA), easily accessible simultaneously with the preparation of the site for pedicle screw insertion during spinal procedures, is becoming...” PMID 32139727 ↗ Mar 2020 |